CALCA and neoplasm: A phase II trial evaluating response, survival, and long-term safety of 90Y-DOTATOC in patients with metastatic MTC and increasing tumor marker calcitonin showed that 29% of patients demonstrated a decrease in tumor marker which was associated with a significantly higher survival 24.